CONCORD

Concord Drugs Share Price

₹37.39 +0.47 (1.27%)

23 Dec, 2024 08:06

SIP TrendupStart SIP in CONCORD

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month + 3.95%
  • Over 3 Month + 3.49%
  • Over 6 Month -4.08%
  • Over 1 Year -12.95%
SIP Lightning

Smart Investing Starts Here Start SIP with Concord Drugs for Steady Growth!

Invest Now

Concord Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Concord Drugs Financials

Concord Drugs Technicals

EMA & SMA

Current Price
₹37.39
+ 0.47 (1.27%)
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹37.00
  • 50 Day
  • ₹36.86
  • 100 Day
  • ₹37.02
  • 200 Day
  • ₹37.17

Resistance and Support

37 Pivot Speed
  • R3 39.59
  • R2 38.60
  • R1 37.99
  • S1 36.39
  • S2 35.40
  • S3 34.79

What's your outlook on Concord Drugs?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Concord Biotech Limited is an R&D-driven biopharma company with two API units and one formulation unit in Gujarat, India. The company supplies APIs and finished formulations across 70+ countries, including the USA, Europe, Japan, and India.

Concord Biotech Ltd has an operating revenue of Rs. 1,085.75 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 40% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 7% and 23% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 20% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 70 which is a FAIR score but needs to improve its earnings, a RS Rating of 65 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Concord Drugs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results
2024-08-09 Quarterly Results
2024-05-30 Audited Results (Revised)
2024-02-13 Quarterly Results
2023-11-14 Quarterly Results

Concord Drugs F&O

Concord Drugs Shareholding Pattern

44.08%
4.97%
4.3%
8.1%
7.33%
31.22%

About Concord Drugs

  • NSE Symbol
  • CONCORD
  • BSE Symbol
  • 538965
  • Chairman & Managing Director
  • Mr. Sudhir Vaid
  • ISIN
  • INE858L01010

Similar Stocks to Concord Drugs

Concord Drugs FAQs

Concord Drugs share price is ₹37 As on 23 December, 2024 | 07:52

The Market Cap of Concord Drugs is ₹37.4 Cr As on 23 December, 2024 | 07:52

The P/E ratio of Concord Drugs is -73.4 As on 23 December, 2024 | 07:52

The PB ratio of Concord Drugs is 1.1 As on 23 December, 2024 | 07:52

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23